Phase-II trial of rebeccamycin analog, a dual topoisomerase-I and -II inhibitor, in relapsed "sensitive" small cell lung cancer
about
The cell competition-based high-throughput screening identifies small compounds that promote the elimination of RasV12-transformed cells from epithelia.Cytotoxic Indolocarbazoles from Actinomadura melliaura ATCC 39691Strategies for the Optimization of Natural Leads to Anticancer Drugs or Drug Candidates.Natural Products Diversity of Marine Ascidians (Tunicates; Ascidiacea) and Successful Drugs in Clinical Development.Microbial natural products: molecular blueprints for antitumor drugs.Topo2A as a prognostic biomarker for patients with resectable esophageal squamous cell carcinomas.
P2860
Phase-II trial of rebeccamycin analog, a dual topoisomerase-I and -II inhibitor, in relapsed "sensitive" small cell lung cancer
description
2012 nî lūn-bûn
@nan
2012 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
Phase-II trial of rebeccamycin ...... sitive" small cell lung cancer
@ast
Phase-II trial of rebeccamycin ...... sitive" small cell lung cancer
@en
type
label
Phase-II trial of rebeccamycin ...... sitive" small cell lung cancer
@ast
Phase-II trial of rebeccamycin ...... sitive" small cell lung cancer
@en
prefLabel
Phase-II trial of rebeccamycin ...... sitive" small cell lung cancer
@ast
Phase-II trial of rebeccamycin ...... sitive" small cell lung cancer
@en
P2093
P2860
P1476
Phase-II trial of rebeccamycin ...... sitive" small cell lung cancer
@en
P2093
Afshin Dowlati
Anita Schwandt
Balazs Halmos
Patrick C Ma
Tarek Mekhail
Timothy O'Brien
P2860
P304
P356
10.1097/JTO.0B013E31824ABCA2
P50
P577
2012-04-01T00:00:00Z